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Background: Oral flucloxacillin, either alone or in combination with phenoxymethylpenicillin, is a commonly
prescribed antibiotic for the treatment of cellulitis, particularly in Ireland and the United Kingdom. This study aims
to establish the non-inferiority of oral monotherapy (flucloxacillin alone) to dual therapy (flucloxacillin and
phenoxymethylpenicillin) for the outpatient treatment of cellulitis in adults.
Methods/design: This study is a multicentre, randomised, double-blind, placebo-controlled trial of adults who
present to the emergency department (ED) with cellulitis that is deemed treatable on an outpatient basis with oral
antibiotics. After fulfilling specified inclusion and exclusion criteria, informed consent will be taken. Patients will be
given a treatment pack containing 7 days of treatment with flucloxacillin 500 mg four times daily and placebo or
flucloxacillin 500 mg four times daily and phenoxymethylpenicillin 500 mg four times daily. The primary outcome
measure under study is the proportion of patients in each group in which there is greater than or equal to a 50%
reduction in the area of diameter of infection from the area measured at enrolment at the end-of-treatment visit
(7 to 10 days). Secondary endpoints include a health-related quality of life measurement as rated by the SF-36 score
and the Extremity Soft Tissue Infection Score (not validated), compliance and adverse events. Patients will be
followed up by telephone call at 3 days, end-of-treatment visit (EOT) at 7 to 10 days and test-of-cure (TOC) visit at 30
days. To achieve 90% power, a sample size of 172 patients per treatment arm is needed. This assumes a treatment
success rate of 85% with oral flucloxacillin and phenoxymethylpenicillin, an equivalence threshold Δ = 12.5% and an
α = 0.025. Non-inferiority will be assessed using a one-sided confidence interval on the difference of proportions
between the two groups. Standard analysis including per-protocol and intention-to-treat will be performed.
Discussion: This trial aims to establish the non-inferiority of flucloxacillin monotherapy to dual therapy in the
treatment of uncomplicated cellulitis among ED patients. In doing so, this trial will bridge a knowledge gap in this
understudied and common condition and will be relevant to clinicians across several different disciplines.
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Cellulitis is an acute, subacute or chronic inflammation
of the dermis and subdermal tissues usually caused by a
bacterial infection [1]. Current use tends to regard the
term erysipelas as a form of cellulitis rather than as a
distinct entity in which a raised leading edge represents
dermal inflammation alone [2]. Indeed, the terminology
used to describe various types of skin and soft tissue in-
fection (SSTI) is complicated because of the use of terms
to describe different types of infection (cellulitis, erysip-
elas, abscess), clinical scenarios (Fournier gangrene) and
aetiological agents (‘clostridial myonecrosis’) [3].
Cellulitis is an understudied condition and the num-
bers of patients seen and treated in Irish emergency
departments (EDs) is unknown. In 2009 in Ireland it
accounted for 3,877 hospital admissions resulting in a
median hospital length-of-stay (LOS) of 4 days [4]. In
the United Kingdom, one survey showed that it accounted
for 3% of emergency visits to a district hospital [5] and re-
sults in approximately 69,576 hospital admissions annually
[6]. In the Netherlands, cellulitis and erysipelas accounted
for 3,500 hospitalisations in 1999 to 2001, with an average
LOS of 12.1 days [7]. The population prevalence in the
same year was 15.2/100,000 inhabitants, with ten times as
many patients treated in the community as in hospital.
In the era of community acquired methicillin resistant
Staphylococcus aureus (CA-MRSA) infection in the
United States, outpatient visits for purulent skin and soft
tissue infection increased from 32.1 to 48.1 per 1,000
population between 1997 and 2005 [8] with a four-fold
increase in hospitalisation rate for cellulitis/abscess be-
tween 1999 and 2005 [9]. Cellulitis and erysipelas cost on
average €5,300 per hospitalised patient in the Netherlands
in 1999 to 2001, with total costs of €13.7 million [7].
Staphylococcus aureus and β-haemolytic Streptococci
Lancefield Group A, C and G are the most common
causative agents of cellulitis [10]. In a recent systematic
review examining the bacteriological etiology of cellulitis
in intact skin, Chira et al. [11] examined 16 trials in-
volving 808 patients. Only 16% had positive cultures, of
which Staphylococcus aureus was almost twice as com-
monly isolated as Streptococcus Group A. This finding
is especially relevant in North America where the onset
of true CA-MRSA infection has reached epidemic pro-
portions [8,10]. Enterococci are occasionally isolated, usu-
ally in patients with leg ulcers, and anaerobic bacteria
are the least commonly isolated subgroup and include
Peptostreptococcus species, Bacteroides fragilis, Prevotella
species, Porphyromonas species and Clostridium species
[1]. In clinical practice, the majority of these infections
can be treated on an outpatient basis with European
[12-14] and North American [15] prescribing guidelines
recommending beta-lactam antibiotics active against
gram-positive bacteria. Despite the increase in CA-MRSA,the Infectious Diseases Society of America (IDSA) also
still recommends beta-lactam antibiotics for ‘non-purulent’
cellulitis [15].
Cellulitis is clinically apparent as an area of spreading
erythema characterised by warmth, pain and tenderness
to palpation. It is on a spectrum of disease from mild
infections, easily treatable with oral antibiotics, to severe
necrotizing infections with associated high mortality.
However, most people are not seriously ill and have a
low risk of complications [16].
Measures of severity
There are no internationally accepted criteria for ‘mild,
moderate and severe’ cellulitis although this classification
scheme is widely used in clinical practice [1]. The classi-
fication used by Eron et al. [16], (Table 1) is useful for
guiding treatment decisions for patients with cellulitis. It
has been used in local National Health Service (NHS)
policy guidelines [17] and is recommended by the Cli-
nical Resource Efficiency Support Team (CREST) group
in Northern Ireland in its consensus statement on the
management of cellulitis [5].
The single ‘best antibiotic’ for treating cellulitis is unknown
[1] and thus there is considerable variability in the class, dose
and regimen of antibiotic prescribed [18]. Flucloxacillin
either alone or in combination with phenoxymethylpenicillin
or its intravenous form, benzylpenicillin, are commonly
prescribed in Great Britain and Ireland [19,20]. Various
sources including authoritative textbooks [21], the na-
tional prescribing formulary in the United Kingdom [22]
and local guidelines, provide conflicting information on
whether monotherapy with flucloxacillin or dual therapy
with combined flucloxacillin and phenoxymethylpenicillin
is optimal, particularly for cellulitis treatable on an
outpatient basis. Recent evidence has shown that oral
phenoxymethylpenicillin prevents cellulitis recurrence in
patients with two or more episodes of leg cellulitis [23].
A study comparing the efficacy, tolerability and com-
pliance of combined oral flucloxacillin and phenoxyme-
thylpenicillin with flucloxacillin alone in the outpatient
treatment of cellulitis would provide a valuable resource
for clinicians, and may close a gap in the research-based
knowledge of this condition.
Methods/design
Study aims
To determine whether flucloxacillin monotherapy is
non-inferior to combined flucloxacillin and phenoxyme-
thylpenicillin (dual therapy) in the management of Eron
Class I and II cellulitis.
Study design and setting
It is intended to carry out a phase 4, multicentre, active-
controlled, double-blind, non-inferiority randomised trial
Table 1 Eron classification system for patients with skin and soft tissue infection [16]
Class Patient criteria
1 Afebrile and healthy, other than cellulitis
2 Febrile and ill appearing, but no unstable comorbidities, or systemically well with comorbidity (PVD, CVI, morbid obesity)
3 Toxic appearance, or at least one unstable comorbidity, or a limb-threatening infection
4 Sepsis syndrome or life-threatening infection, for example, necrotizing fasciitis
CVI chronic venous insufficiency, PVD peripheral vascular disease.
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nically treatable with an oral antibiotic as an outpatient
(Eron Class I and II cellulitis). Patients will be random-
ized to receive either flucloxacillin and phenoxyme-
thylpenicillin or flucloxacillin and placebo in a 1:1 ratio.
Ethical considerations
This study is to be performed in accordance with the Good
Clinical Practice (GCP) Guidelines, the EU CT Directive
2001/20.EC, GCP Commission Directive 2005/28/EC, the
Declaration of Helsinki (2008) and with all other local regu-
latory requirements. Risk Analysis was carried out as part
of protocol development. The study protocol was approved
by Beaumont Hospital Research and Ethics Committee.
Patients will be enrolled from the ED they attend. This may
be by self-referral or general practitioner (GP) referral.
Regulatory considerations
The Irish Medicines Board (IMB) is the competent au-
thority for the review and approval of clinical trials withTable 2 Inclusion and exclusion criteria
Inclusion criteria
>16 years of age
Cellulitis of any body area excluding the perineum, that is treatable with oral
antibiotic as an outpatient and in whom either combination of antibiotic is l
to produce a clinical response






Fluency in written and spoken Englishan investigational medicinal product (IMP) in Ireland.
The application process for a medicinal trial was suc-
cessful after formal engagement with the IMB prior to
application and during the application process. IMB
approval for this trial was granted on 30 January 2009.
Subject selection
Patients more than 16 years of age satisfying the inclusion
and exclusion criteria (Table 2) who present to the re-
cruiting EDs with cellulitis during the study period, will be
eligible for recruitment into the trial. All potential patients
will be given time to read the patient information leaflet
prior to informed consent being taken. Once consent is
signed, the enrolment procedure will continue to random
selection of the drug pack. Enrolment will be undertaken
by any of the following: a hospital doctor with minimum 2
years experience in Emergency Medicine (including con-
sultants, specialist registrars, associate specialists and non-
specialist registrars) and Advanced Nurse Practitioners
who are registered prescribers of medications.Exclusion criteria
Any cellulitis that requires intravenous antibiotic
ikely




Chronic skin condition at the site of infection
Infection involving prosthetic material
Thermal injury
Acne vulgaris
Perineal cellulitis (high risk of anaerobic infection)
Fungal infection of scalp or nail bed
Immunodeficiency
Severe renal or hepatic dysfunction
Concomitant treatment with oral, parenteral or topical antibiotics
at infection site
Patients taking systemic corticosteroids at a dose exceeding 15
mg (or equivalent) per day for more than 7 days
Refusal or inability to give informed consent
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Inclusion and exclusion criteria are presented in Table 2.
Patient randomisation
The randomisation process has been designed by CSTAR
(Health Research Board Centre for Support and Training in
Analysis and Research), Dublin, Ireland. Trial randomisation
codes will be generated by CSTAR. It is intended to use
block randomization using a permuted block design with a
computer random number generator without stratification,
to create two treatment groups of 172 patients (n = 344).
Randomisation treatments
Allocation concealment
A sequentially numbered opaque sealed envelope (SNOSE)
will be opened for each patient who consents to enrollment
into the study. This envelope will be opaque to intense
light. It will contain a copy of the information leaflet, a
consent form, an SF-36 and ESTI score, a paper tape
measure, the study drugs in two amber containers, and a
patient proforma with a unique pre-printed patient identi-
fier to be used throughout the study. The proforma will be
inserted in to the ED notes and scanned or stored securely
as is standard practice with patient data in the EDs in
question. The proforma will then be re-used for the end-
of-treatment (EOT) and test-of-cure (TOC) visits. The
SNOSEs will be stored in the secure Specialist Registrar
Office available in each location, which will be accessible
at all times. All study drugs will be packaged by the clin-
ical trial pharmacist who will remain independent of all
further patient treatments.
Drug appearance
Phenoxymethylpenicillin appears as a circular round
white tablet with a marking ‘PEN 500’ on the side
(SmPC Athlone Laboratories Limited, Ballymurray, Co.
Roscommon, Ireland). The placebo formulation to be
used will also be a white round tablet with a notch and
contain lactose monohydrate, magnesium stearate and
cellulose (FAGRON GmbH & Co. KG Von-Bronsart-Straße
12, 22885 Barsbüttel, Germany. www.fagron.de).
Flucloxacillin appears as a caramel coloured, hard capsule
marked with ‘FXN 250’ or ‘FXN 500’. Since both groups
are receiving flucloxacillin, product blinding is irrelevant.
All efforts will be made to ensure placebo and pheno-
xymethylpenicillin tablets are similar in appearance; it
should be possible to have a dummy inscription on the
placebo tablet.
Product liability
Public and product liability is in place for licensed medica-
tions issued by Athlone Laboratories and includes cover
for the generic brands of phenoxymethylpencillin and
flucloxacillin to be used in the study.Breaking of the study blind
On study
If an adverse event is regarded as a potential Serious Un-
expected Suspected Adverse Reaction (SUSAR) by the
sponsor the treatment group to which the trial subject af-
fected belongs will be unblinded for that subject alone.
The procedure will ensure that the identity of the investi-
gational medicinal product (IMP) is only revealed as far as
necessary (GCP Directive). All staff will have received
training on all aspects of the trial protocol prior to com-
mencement of the trial.
The principal investigator (PI) or authorised member of
the team will have a written procedure for requesting ran-
domisation codes for rapidly identifying a blinded IMP in
an emergency. Breaking the blind of a trial subject will be
at the discretion of the PI, when clinically indicated for
the safety of the patient, or in the event of a SUSAR. If the
patient needs to be unblinded we will refer to the
unblinding SOP for complete details of the procedures to
be followed. The master randomisation codes will be kept
by the clinical trial Pharmacist and the PI. Unblinding will
be performed by the senior clinician/pharmacist when the
criteria for a Serious Adverse Event (SAE/SUSAR) have
been met and there is a necessity for the PI or treating
healthcare professional to know which treatment the pa-
tient is receiving to ensure that the patient receives appro-
priate urgent safety measures.
A 24-hour contact number will be available in the cir-
cumstances when unblinding is required. The scenario
will be communicated and when the unblinding criteria
are met the unblinding will ensue. The PI will document
the breaking of the code, and the reasons for doing so,
in the site file and in the patient’s medical notes, and in
accordance with the clinical trial protocol. If at the EOT
visit a clinical failure is apparent and the addition of
phenoxymethylpenicillin is felt to be clinically necessary,
code breaking will be made possible on a 24-hour basis
by making contact with the PI. It is felt that unblinding
will be an extremely unlikely event as a treatment failure
will more than likely require intravenous antibiotics.
Any compromises in blinding will be reported in the
trial conclusion.
Following completion of the study
Study unblinding will only take place once the statistical
analysis plan has been agreed by the trial team and the
final database has been locked.
Study procedure
Interventions
Wound/skin care Standard wound care for cellulitis will
be permissible in both groups and may include saline soaks
and non-adherent dressings. The area of infection will be
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diameter of the area of infection measured and recorded.
Microbiological assay Whenever possible a specimen
for culture and sensitivity will be taken from the infec-
tion site at enrolment. This may be from blister fluid or
exudate. Specimen results will be made available at
follow-up to guide appropriate therapy. Blood cultures
will not be taken in this study. Since the expected micro-
biological yield will be low, a test of microbiological cure
will not be used in this study.
Therapeutic intervention Once enrolled patients will
be given a 7-day course of either oral flucloxacillin 500
mg four times daily and oral phenoxymethylpenicillin
500 mg four times daily or oral flucloxacillin 500 mg
four times daily and oral placebo four times daily.
Follow-up Patients will be telephoned at 3 to 5 days by
a study investigator to encourage treatment compliance
and EOT visit follow-up. Any deterioration in patient
symptoms may be addressed at this visit and a return for
clinical assessment may be recommended. The patient
will be reviewed at 7 to 10 days after treatment com-
mencement (EOT visit) in the enrolment centre and the
area of infection will be measured. At this visit, the pa-
tient will be given an SF-36 and ESTI score to complete.
A final TOC visit or telephone call will be arranged for
30 days after the enrolment of the patient into the trial.
Outcome measures
Primary outcome The primary outcome measure under
study is the proportion of patients treated in each group
in which there is greater than or equal to a 50% reduc-
tion in the maximal diameter of erythema from the area
measured at enrolment to that at the end-of-treatment
visit (7 to 10 days).
Measurement of the primary outcome Clinical cure:
Reduction in the area of cellulitis by ≥50% of the initial
diameter.
Secondary outcomes
 Clinical failure: a failure of the initial maximal
diameter of infection to reduce by ≥50%
 Clinical relapse: initial improvement in cellulitis at
the EOT visit followed by a worsening or re-
appearance of cellulitis at the TOC visit.
 Quality of life: the SF-36 and the ESTI score at the
EOT visit will be measured.
 Compliance with therapy: the number of unused
study medications counted at the EOT visit will be
measured. Adverse Events: all adverse events will be recorded
and submitted to the Irish Medicines Board and the
Research and Ethics Committee.
 Microbiological profile: the results of specimens sent
for culture to receiving laboratories will be profiled.
Sample size, power and statistical methods
Non-inferiority of oral flucloxacillin and placebo relative
to oral flucloxacillin and phenoxymethylpenicillin for the
above primary and secondary outcomes will be assessed.
Sample size per treatment arm is calculated according to
an assumed treatment success rate of 85% with oral
flucloxacillin and phenoxymethylpenicillin, an equiva-
lence threshold Δ = 12.5% and an α = 0.025 (as this is a
non-inferiority study). Sample sizes were calculated
using PASS statistical software (Hintze J.(2008) PASS
2008. NCSS, LLC, Kaysville, Utah, USA www.ncss.com).
Given the preferred study power of 90% for non-
inferiority trials, a minimum sample size of 172 in each
treatment group is required (n = 344). Non-inferiority
will be assessed using a one-sided confidence interval
(CI) on the difference of proportions between the two
groups. If the upper limit of the CI is less than the
equivalence threshold of 12.5%, then non-inferiority is
inferred.
Data analysis
Both intention-to-treat (ITT) and per-protocol analysis
will be performed. ITT analyses include all patients
randomised to the trial regardless of whether they sa-
tisfied entry requirements, received the assigned treat-
ments, withdrew from the trial or adhered to the
protocol. Missing values will be imputed using a suitable
imputation method (last value carried forward or mixed
model). A per-protocol analysis includes only patients
who completed the full course of treatment and adhered
to the protocol requirements. In a non-inferiority trial
setting a per-protocol analysis may be more appropriate
since it is more likely to reflect actual differences be-
tween the two treatments. Furthermore, ITT analysis
may be interpreted as being too liberal in a non-
inferiority trial and may bias toward making the two
treatments appear similar [24]. As a result, both an ITT
and per-protocol analysis will be performed on the
resulting data to assess non-inferiority of the placebo/
flucloxacillin combination. In particular, to declare non-
inferiority, both ITT and per protocol analysis should
exclude the non-inferiority margin.
Bias and confounding variables
In terms of selection bias, we feel that this study targets
a patient population to whom this research ultimately
will be clinically applicable and valuable. Every effort will
be made to ensure that recruitment of participants
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having patients recruited by the ED physician treating
the patient. We anticipate that the randomised, double-
blinded, controlled design of this study will minimise the
effect of confounding variables on our analysis.
Safety reporting
All adverse events that occur during the study period
observed by one of the clinical staff, or reported by the
patient or parent/guardian spontaneously, or in response
to a direct question, will be noted on the appropriate
form (that is, Adverse Event (AE), SAE or SUSAR form).
These forms are de-identified. The following procedures
will take place depending on the type of event that has
occurred.
Adverse event Each AE will be recorded by a member
of the research team on an AE Form. Adverse events
will be classified on the form in terms of their severity,
association with the study drug, expectedness and ser-
iousness. They will be recorded on an Adverse Event
Log. The adverse events will be reported to the sponsor
and to the institutional Health Research Ethics Commit-
tee (HREC) on a yearly basis as part of an annual safety
report, and at the end of the trial.
Serious adverse event Each SAE will be recorded by a
member of the research team on an SAE Form. SAEs
will be classified on the form in terms of their severity,
relatedness to the study drug, and expectedness. They
will be recorded on a Serious Adverse Event Log. All
SAEs will be reported on the SAE form within 24 hours
to the sponsor and the institutional HREC. The research
team will ensure that follow-up information and a de-
tailed written report are provided when available.
Suspected unexpected serious adverse drug reactions
Each SUSAR will also require expedited reporting to the
sponsor. This will occur as soon as possible, but no later
than 24 hours after a member of the research team has
first knowledge of the minimum criteria for expedited
reporting. In each case, relevant follow-up information
will be sought and a detailed, written report completed
as soon as possible. The sponsor has responsibility to en-
sure all relevant and available information is forwarded to
the competent authority (Irish Medicines Board) and the
appropriate HREC. For fatal or life-threatening events this
will be done as soon as possible and not later than seven
days after the sponsor becomes aware of the event.
Additional relevant information will be sent within eight
days of the first report. This will be sent no later than an
additional 15 calendar days. For AEs that are not fatal or
life threatening, the sponsor will ensure that a SUSAR isreported as soon as possible and in any event not later
than 15 days after the sponsor is first aware of the event.
The study participants will be provided with 24-hour
contact details of a study representative if they have con-
cerns about any component of the study.
Trial status
This trial requires further funding in order to commence
enrolment.
Abbreviations
AE: Adverse event; CA-MRSA: Community acquired methicillin resistant
Staphylococcus aureus; CI: Confidence interval; CSTAR: Centre for support and
training in analysis and research; CREST: Clinical resource efficiency support
team; ED: Emergency department; EOT: End-of-treatment; GCP: Good clinical
practice; GP: General practitioner; HREC: Health research ethics committee;
IMB: Irish medicines board; ITT: Intention to treat; LOS: Length of stay;
NHS: National health service; PI: Principal investigator; SAE: Serious adverse
event; SNOSE: Sequentially numbered opaque sealed envelope;
SOP: Standard operating procedure; SSTI: Skin and soft tissue infection;
SUSAR: Suspected unexpected serious adverse reaction; TOC: Test-of-cure.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MQ, PG, AW and ROS conceived the study and each made substantial
contributions to design; all have been involved in drafting the manuscript
and revising it critically for intellectual content; and have given final approval
of the version to be published.
Acknowledgements
Statistical advice for this protocol was provided by Ms. Norma Coffey from
the School of Mathematical Sciences/Systems Biology Ireland, University
College Dublin (UCD), Ireland. This study has received funding from the
College of Emergency Medicine, UK.
Author details
1Division of Population Health Sciences (PHS), Emergency Care Research Unit
(ECRU), Royal College of Surgeons in Ireland, 123 St. Stephens Green, Dublin
2, Ireland. 2Emergency Department, Beaumont Hospital, PO Box 1297,
Beaumont Road, Dublin 9, Ireland. 3Paediatric Emergency Research Unit
(PERU), National Children’s Research Centre, Dublin 12, Ireland. 4Department
of Emergency Medicine, Cork University Hospital, Wilton, Cork, Ireland.
Received: 21 February 2013 Accepted: 17 May 2013
Published: 3 June 2013
References
1. Kilburn S, Featherstone P, Higgins B, Brindle R: Interventions for cellulitis
and erysipelas. Cochrane Database Syst Rev 2010, 16, CD004299.
2. Hay RJ, Adriaans BM: Bacterial Infections. In Rook’s Textbook of Dermatology.
Volume 2. 7th edition. Edited by Burns DA, Breathnach SM, Cox NH, Griffiths
C. Oxford: Blackwell Publishing; 2004:27. 16–27.20.
3. Gunderson CG: Cellulitis: definition, etiology and clinical features.
Am J Med 2011, 124:1113–1122.
4. The Economic and Social Research Institute (ESRI). http://www.esri.ie/
health_information/hipe_data_reporter/prepare_report/report.xml.
5. CREST (Clinical Resource Efficiency Support Team): Section 1; Introduction.
In CREST guidelines on the management of cellulitis in adults. Edited by
CREST. DHSS Northern Ireland; 2005:1–31.
6. Hospital Episode Statistics. http://www.hesonline.nhs.uk/.
7. Goettsch WG, Bouwes Bavinck JN, Herings RMC: Burden of illness of
bacterial cellulitis and erysipelas of the leg in the Netherlands.
JEADV 2006, 20:834–839.
8. Hersh AL, Chambers HF, Maselli JH, Gonzales R: National trends in
ambulatory visits and antibiotic prescribing for skin and soft-tissue
infections. Arch Int Med 2008, 168:1585–1591.
Quirke et al. Trials 2013, 14:164 Page 7 of 7
http://www.trialsjournal.com/content/14/1/1649. Klein E, Smith DL, Laxminarayan R: Hospitalizations and deaths caused by
methicillin-resistant Staphylococcus aureus, United States, 1999–2005.
Emerg Infect Dis 2007, 13:1840–1846.
10. Dryden MS: Skin and soft tissue infection: microbiology and
epidemiology. Int J Antimicrob Agents 2009, 34(Suppl 1):S2–S7.
11. Chira S, Miller LG: Staphylococcus aureus is the most common identified
cause of cellulitis: a systematic review. Epidemiol Infect 2010, 138:313–317.
12. Schöfer H, Bruns R, Effendy I, Hartmann M, Jappe U, Plettenberg A, Reimann
H, Seifert H, Shah P, Sunderkötter C, Weberschock T, Wichelhaus TA, Nast A,
German Society of Dermatology (DDG)/ Professional Association of German
Dermatologists (BVDD); Infectious Diseases Society of Germany (DGI);
German Society for Hygiene and Microbiology (DGHM); German Society for
Pediatric Infectious Diseases (DGPI); Paul Ehrlich Society for Chemotherapy
(PEG): Diagnosis and treatment of Staphylococcus aureus infections of the
skin and mucous membranes. J Deutsch Dermatol Ges 2011, 9:953–967.
13. PRODIGY: Acute cellulitis; 2011. http://prodigy.clarity.co.uk/cellulitis_acute/
view_whole_topic.
14. [Management of erysipelas and necrotising fasciitis] Article in French.
Ann Dermatol Venereol 2001, 128:458–462.
15. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL,
Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF,
Infectious Diseases Society of America: Clinical practice guidelines by the
Infectious Diseases Society of America for the treatment of methicillin-
resistant Staphylococcus aureus infections in adults and children.
Clin Infect Dis 2011, 52:e18–e55.
16. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA: Managing
skin and soft tissue infections: expert panel recommendations on key
decision points. J Antimicrob Chemother 2003, 52(Suppl 1):i3–i17.




18. Leman P, Mukherjee D: Flucloxacillin alone or combined with
benzylpenicillin to treat lower limb cellulitis: a randomised controlled
trial. Emerg Med J 2005, 22:342–346.
19. Cox NH: Management of lower leg cellulitis. Clin Med 2002, 2:23–27.
20. Anonymous: Dilemmas when managing cellulitis. Drug Ther Bull 2003,
41:43–46.
21. Morris A: Cellulitis and erysipelas. Clin Evid 2002, 7:1483–1487. Update in:
Clin Evid 2003, 9:1804–1809.
22. British Medical Association and the Royal Pharmaceutical Society of Great
Britain: British National Formulary. 58th edition. London, UK: BMJ Publishing
Group; 2009.
23. UK Dermatology Clinical Trials Network’s PATCH Trial Team, Thomas K,
Crook A, Foster K, Mason J, Chalmers J, Bourke J, Ferguson A, Level N, Nunn
A, Williams H: Prophylactic antibiotics for the prevention of cellulitis
(erysipelas) of the leg: results of the UK Dermatology Clinical Trials
Network’s PATCH II trial. Br J Dermatol 2012, 166:169–178.
24. D’Agostino RB Sr, Massaro JM, Sullivan LM: Non-inferiority trials: design
concepts and issues – the encounters of academic consultants in
statistics. Stat Med 2003, 22:169–186.
doi:10.1186/1745-6215-14-164
Cite this article as: Quirke et al.: Oral flucloxacillin and
phenoxymethylpenicillin versus flucloxacillin alone for the emergency
department outpatient treatment of cellulitis: study protocol for a
randomised controlled trial. Trials 2013 14:164.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
